Barclays lowered the firm’s price target on WW to 75c from $1.50 and keeps an Underweight rating on the shares. The company reported a disappointing Q2 print that featured a revenue miss, fiscal 2024 guidance cut and weak metrics, the analyst tells investors in a research note. The firm says WW also announced a restructuring plan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- WW Earnings this Week: How Will it Perform?
- WW International (NASDAQ:WW) Plummets as Morgan Stanley Downgrades Stock
- Lockheed Martin upgraded, L3Harris downgraded: Wall Street’s top analyst calls
- WW downgraded to Equal Weight from Overweight at Morgan Stanley
- WW chief medical officer to step down after less than a year, Bloomberg says